Tirzepatide was originally developed to treat Type-2 diabetes but has since become a leading anti-obesity medication. It is a dual agonist of the GLP-1 and GIP receptors — meaning it activates two distinct hormonal pathways to reduce appetite, improve metabolic rate, and support sustained weight loss.
MECHANISM OF ACTION
GLP-1: Suppresses appetite and increases feelings of fullness after eating.
GIP: Promotes insulin secretion and supports energy balance through receptors in the hypothalamus.
